Cardiol Therapeutics to Advance CardiolRx(TM) Into a Late-Stage Trial in Patients With Recurrent Pericarditis

newsfileOct 22 06:30 ET

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

newsfileOct 10 09:09 ET

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

newsfileOct 9 07:58 ET

Cardiol Therapeutics Prices $13.5M Public Offering | TSX:CRDL, NASDAQ:CRDL

Proactive InvestorsOct 9 05:10 ET

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

newsfileOct 8 16:01 ET

Cardiol Therapeutics Achieves Target Patient Enrollment in Its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

newsfileSep 24 07:27 ET